Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
44,600,309
-
Share change
-
-6,540,216
-
Total reported value
-
$53,054,739
-
Put/Call ratio
-
47%
-
Price per share
-
$1.19
-
Number of holders
-
86
-
Value change
-
-$16,229,688
-
Number of buys
-
39
-
Number of sells
-
38
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q1 2022
As of 31 Mar 2022,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,600,309 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, FMR LLC, BlackRock Inc., Artal Group S.A., Ally Bridge Group (NY) LLC, Flagship Pioneering Inc., Omega Fund Management, LLC, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., and Samsara BioCapital, LLC.
This page lists
86
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.